Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01185613
Other study ID # AF-09-024-EU-AB
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date June 2010
Est. completion date September 2011

Study information

Verified date February 2019
Source Abbott Medical Devices
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to observe the performance of Therapy™ Cool Flex™ catheter by documenting the procedural parameters, major complications and recurrence of AF after ablation using Cool Flex ablation catheter for the treatment of paroxysmal atrial fibrillation.

This study is an observational clinical study which is not based on any specific endpoints.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date September 2011
Est. primary completion date September 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- A signed written Informed Consent form

- 18 years of age or older

- Agrees to comply with follow-up visits and evaluation

- Candidate for catheter ablation for the treatment of paroxysmal atrial fibrillation as per the hospital standard of care.

Exclusion Criteria:

- Persistent or Long standing AF

- CABG procedure within the last 180 days (six months).

- Documented left atrial thrombus on imaging [e.g. Transesophageal echocardiogram (TEE)].

- History of blood clotting or bleeding abnormalities.

- Contraindication to anticoagulation (i.e. heparin or warfarin).

- Enrollment in another investigational study evaluating device or drug that might impact the results of this study.

- Women who are pregnant (by history of menstrual period or pregnancy test if the history is considered unreliable).

- Acute illness or active systemic infection or sepsis.

- Life expectancy less than 12 months.

- Uncontrolled heart failure or NYHA class IV heart failure.

- Myocardial Infarction within 8 weeks of enrollment or unstable angina

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Therapy™ Cool Flex Ablation Catheter
The device under evaluation is the 4mm Therapy™ Cool Flex Ablation Catheter. The Therapy™ Cool Flex catheter is a flexible tip, insulated, 7F catheter constructed of thermoplastic elastomer material and noble metal electrodes. The following CE Mark devices will be used in conjunction with the Therapy™ Cool Flex Ablation Catheter IBI-1500T11 Cardiac Ablation Generator (RF ablation generator) with software version 3.0 or higher. Cool Point™ Irrigation Pump Cool Point™ Tubing set Data Logger

Locations

Country Name City State
Australia Royal Adelaide Hospital Adelaide
France Hopital du Haut Leveque Pessac
Germany Universitat Leipzig Herzzentrum Leipzig
Italy Ospendale dell'Angelo Mestre
Portugal Hospital Santa Cruz Lisbon
United Kingdom Heart Hospital London

Sponsors (1)

Lead Sponsor Collaborator
Abbott Medical Devices

Countries where clinical trial is conducted

Australia,  France,  Germany,  Italy,  Portugal,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Procedural parameters Ablation parameters (such as average power delivered , average tip temperature , average impedance )
Lesion locations (such as PVI, Septal line, Mitral isthmus, CTI or any other lesion location)
Mapping techniques (Mapping system and catheter)
RF application time ( Calculated from the total number of RF application and duration of each RF application)
Ablation procedure time (Time from the first to the last RF application)
Total irrigation fluid administered during ablation procedure
Fluoroscopy time
6 months
Primary AF Recurrence Recurrence of AF through six months post last RF ablation procedure using Cool Flex catheter. A 24 hour Holter will be provided to the patients for six month follow-up visit in order to monitor AF episodes. An AF episode will be considered a recurrence only if it lasts for 30 seconds or more.
AF recurrences during the blanking period (defined below) will not be reported.
6 months
Primary Serious Adverse Events All serious adverse events through six month follow-up 6 months
See also
  Status Clinical Trial Phase
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Recruiting NCT06014996 - Comparison of PFA vs. RFA in Patients With Symptomatic Paroxysmal Atrial Fibrillation. N/A
Completed NCT03624881 - Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU) Phase 4
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Recruiting NCT05905835 - Treatment of PAF With the Synaptic System N/A
Active, not recruiting NCT05618340 - PFA for Paroxysmal Atrial Fibrillation N/A
Active, not recruiting NCT05534581 - SINGLE SHOT CHAMPION Phase 4
Not yet recruiting NCT05024630 - Renal Denervation and pUlmonary Vein isolAtion With cryoabLation on Patients With Atrial Fibrillation and hypErtension N/A
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Completed NCT01913522 - Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration N/A
Terminated NCT01925885 - Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF) N/A
Withdrawn NCT01917981 - Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation Phase 3
Completed NCT01842529 - Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery Phase 2
Completed NCT01693107 - Atrial Fibrillation Force Contact Ablation Study
Completed NCT00971204 - Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation Phase 2
Completed NCT05043883 - Automated Assessment of PVI Using a Novel EP Recording System N/A
Recruiting NCT05172765 - Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF) N/A
Recruiting NCT04529785 - Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation N/A
Completed NCT04022954 - HD Mapping of Atrial Fibrillation in Asia Pacific
Completed NCT00964392 - NAVISTAR® THERMOCOOL® Catheter Post Approval Registry Phase 4